Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 1
Submit an article Journal homepage
2,011
Views
1
CrossRef citations to date
0
Altmetric
Articles

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Lynda Spelmana Veracity Clinical Research, Brisbane, AustraliaView further author information
,
Diana Rubelb Woden Dermatology, ACT, AustraliaView further author information
,
Alan Brnabicc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information
,
Nicole Burkhardtc Eli Lilly Australia Pty Limited, West Ryde, AustraliaView further author information
,
Elisabeth Riedld Eli Lilly Ges.m.b.H, Vienna, Austria;e Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information
&
Peter Foleyf Skin Health Institute, Carlton, Australia;g The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, AustraliaCorrespondence[email protected]
View further author information
Pages 329-335 | Received 16 Mar 2020, Accepted 01 Apr 2020, Published online: 21 Apr 2020

Related Research Data

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.